Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Can Takeda's Alunbrig Take On Roche's Alecensa In First-Line ALK-Positive Lung Cancer?

Sep 27 2018

• By Emily Hayes

lung illustration

Related Content

Brigatinib Approval Validates Ariad Buy, But Can Takeda Carve A Position?

May 01 2017

Roche’s Alecensa Goes Up Against Zykadia with First-Line NSCLC US FDA Approval

Nov 07 2017

AstraZeneca Makes European IO Debut With Imfinzi Lung Cancer Approval

Sep 25 2018

Tecentriq's Small-Cell Lung Cancer Success Takes Edge Off Roche's IO Position

Sep 26 2018

AstraZeneca's PACIFIC Update Bolsters Imfinzi's Lead In Stage III Lung Cancer

Sep 26 2018

IMpower132 Casts More Doubt On Roche's Tecentriq In First-Line NSCLC

Sep 26 2018

Roche’s Entrectinib Differentiates Itself From NSCLC Competitors With CNS Data

Sep 24 2018

Latecomer Brigatinib Looking Good In First-Line NSCLC Head-To-head

Jul 27 2018

Related Companies

Takeda Pharmaceutical Co. Ltd.

Pfizer Inc.

Novartis AG

Roche Holding AG

Chugai Pharmaceutical Co., Ltd.

Additional Topics

Clinical Trials Research & Development Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window